BiognoSYS is a biotechnology company with a next generation proteomics platform for sensitive and accurate protein quantification. BiognoSYS has developed a targeted proteomics technology that allows simultaneous measurement of hundreds to thousands of proteins in one sample. The technology has been developed for application in both the research and healthcare markets. BiognoSYS is a spin-off from the lab of Prof. Ruedi Aebersold, a pioneer in the field of quantitative proteomics who is based at the Swiss Federal Institute of Technology (ETH).

Michael Lee serves as a director on the Board of BiognoSYS.